TEAD1 and neoplasm: These include VT-107 (38) and K-975 (39, 40), both pan-TEAD inhibitors, and IK-930, a TEAD1-specific inhibitor (41) that has undergone clinical trials (42) for the treatment of PM and other tumours associated with perturbations within the Hippo pathway (NCT05228015).